{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:06:39Z","timestamp":1791576399484,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bengbu Medical University Natural Science Program","award":["2023byzd076"],"award-info":[{"award-number":["2023byzd076"]}]},{"name":"Bengbu Medical University Natural Science Program","award":["2023byzd076"],"award-info":[{"award-number":["2023byzd076"]}]},{"name":"Bengbu Medical University Natural Science Program","award":["2023byzd076"],"award-info":[{"award-number":["2023byzd076"]}]},{"name":"Bengbu Medical University Natural Science Program","award":["2023byzd076"],"award-info":[{"award-number":["2023byzd076"]}]},{"name":"Bengbu Medical University Natural Science Program","award":["2023byzd076"],"award-info":[{"award-number":["2023byzd076"]}]},{"name":"Bengbu Medical University Natural Science Program","award":["2023byzd076"],"award-info":[{"award-number":["2023byzd076"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01793-x","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:13:25Z","timestamp":1753172005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of doxycycline for severe Mycoplasma pneumoniae pneumonia in pediatric patients"],"prefix":"10.1007","volume":"25","author":[{"given":"Qian","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wansheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"1793_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.bjid.2016.04.008","volume":"20","author":"F Huang","year":"2016","unstructured":"Huang F, Lu L, Jiang W, et al. The epidemiology and clinical features of Mycoplasma pneumoniae infection in neonates. Braz J Infect Dis. 2016;20:374\u20138. https:\/\/doi.org\/10.1016\/j.bjid.2016.04.008.","journal-title":"Braz J Infect Dis"},{"key":"1793_CR2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268819000839","volume":"147","author":"LW Gao","year":"2019","unstructured":"Gao LW, Yin J, Hu YH, et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016. Epidemiol Infect. 2019;147: e192. https:\/\/doi.org\/10.1017\/S0950268819000839.","journal-title":"Epidemiol Infect"},{"key":"1793_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/fmicb.2016.00800","volume":"7","author":"K Izumikawa","year":"2016","unstructured":"Izumikawa K. Clinical features of severe or fatal Mycoplasma pneumoniae pneumonia. Front Microbiol. 2016;7:800. https:\/\/doi.org\/10.3389\/fmicb.2016.00800.","journal-title":"Front Microbiol"},{"key":"1793_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1542\/pir.2018-0016","volume":"41","author":"C Krafft","year":"2020","unstructured":"Krafft C, Christy C. Mycoplasma pneumonia in children and adolescents. Pediatr Rev. 2020;41:12\u20139. https:\/\/doi.org\/10.1542\/pir.2018-0016.","journal-title":"Pediatr Rev"},{"key":"1793_CR5","doi-asserted-by":"publisher","first-page":"1306234","DOI":"10.3389\/fped.2023.1306234","volume":"11","author":"Z Song","year":"2023","unstructured":"Song Z, Jia G, Luo G, Han C, Zhang B, Wang X. Global research trends of Mycoplasma pneumoniae pneumonia in children: a bibliometric analysis. Front Pediatr. 2023;11:1306234. https:\/\/doi.org\/10.3389\/fped.2023.1306234.","journal-title":"Front Pediatr"},{"key":"1793_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1424554","volume":"14","author":"J You","year":"2024","unstructured":"You J, Zhang L, Chen W, et al. Epidemiological characteristics of mycoplasma pneumoniae in hospitalized children before, during, and after COVID-19 pandemic restrictions in Chongqing, China. Front Cell Infect Microbiol. 2024;14: 1424554. https:\/\/doi.org\/10.3389\/fcimb.2024.1424554.","journal-title":"Front Cell Infect Microbiol"},{"key":"1793_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.20949","volume":"5","author":"K Kim","year":"2022","unstructured":"Kim K, Jung S, Kim M, Park S, Yang HJ, Lee E. Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis. JAMA Netw Open. 2022;5: e2220949. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.20949.","journal-title":"JAMA Netw Open"},{"key":"1793_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1128\/JCM.02597-14","volume":"53","author":"MH Diaz","year":"2015","unstructured":"Diaz MH, Benitez AJ, Winchell JM. Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin Microbiol. 2015;53:124\u201330. https:\/\/doi.org\/10.1128\/JCM.02597-14.","journal-title":"J Clin Microbiol"},{"key":"1793_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02432-21","volume":"66","author":"TE Rothstein","year":"2022","unstructured":"Rothstein TE, Cunningham SA, Rieke RA, Mainella JM, Mutchler MM, Patel R. Macrolide resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021. Antimicrob Agents Chemother. 2022;66: e0243221. https:\/\/doi.org\/10.1128\/aac.02432-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"1793_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00968-19","author":"KB Waites","year":"2019","unstructured":"Waites KB, Ratliff A, Crabb DM, et al. Macrolide-resistant Mycoplasma pneumoniae in the United States as determined from a national surveillance program. J Clin Microbiol. 2019. https:\/\/doi.org\/10.1128\/JCM.00968-19.","journal-title":"J Clin Microbiol"},{"key":"1793_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00974","volume":"7","author":"S Pereyre","year":"2016","unstructured":"Pereyre S, Goret J, Bebear C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol. 2016;7: 974. https:\/\/doi.org\/10.3389\/fmicb.2016.00974.","journal-title":"Front Microbiol"},{"key":"1793_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011825.pub2","volume":"1","author":"MP Hansen","year":"2019","unstructured":"Hansen MP, Scott AM, McCullough A, et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. 2019;1: CD011825. https:\/\/doi.org\/10.1002\/14651858.CD011825.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1793_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7030135","author":"KM Shaeer","year":"2019","unstructured":"Shaeer KM, Chahine EB, Varghese Gupta S, Cho JC. Macrolide allergic reactions. Pharmacy (Basel). 2019. https:\/\/doi.org\/10.3390\/pharmacy7030135.","journal-title":"Pharmacy (Basel)"},{"key":"1793_CR14","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41390-021-01613-4","volume":"91","author":"J Sun","year":"2022","unstructured":"Sun J, Li Y. Long-term, low-dose macrolide antibiotic treatment in pediatric chronic airway diseases. Pediatr Res. 2022;91:1036\u201342. https:\/\/doi.org\/10.1038\/s41390-021-01613-4.","journal-title":"Pediatr Res"},{"key":"1793_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10020192","author":"H Lee","year":"2021","unstructured":"Lee H, Choi YY, Sohn YJ, et al. Clinical efficacy of doxycycline for treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Antibiotics (Basel). 2021. https:\/\/doi.org\/10.3390\/antibiotics10020192.","journal-title":"Antibiotics (Basel)"},{"key":"1793_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03759.x","volume":"18","author":"B Teh","year":"2012","unstructured":"Teh B, Grayson ML, Johnson PD, Charles PG. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia. Clin Microbiol Infect. 2012;18: E71\u20133. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03759.x.","journal-title":"Clin Microbiol Infect"},{"key":"1793_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s40001-022-00912-8","volume":"27","author":"RK Aldhahri","year":"2022","unstructured":"Aldhahri RK, Gabb SG, Shoaib OA, Almadani RM, Eljaaly K, Thabit AK. Doxycycline vs. macrolides in combination with a \u03b2-lactam antibiotic for the treatment of community-acquired pneumonia in inpatients. Eur J Med Res. 2022;27:279. https:\/\/doi.org\/10.1186\/s40001-022-00912-8.","journal-title":"Eur J Med Res"},{"key":"1793_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3389\/fphar.2019.01088","volume":"10","author":"H Zhang","year":"2019","unstructured":"Zhang H, Mao C, Li J, et al. Pharmacokinetic\/pharmacodynamic integration of doxycycline against Mycoplasma hyopneumoniae in an in vitro model. Front Pharmacol. 2019;10:1088. https:\/\/doi.org\/10.3389\/fphar.2019.01088.","journal-title":"Front Pharmacol"},{"key":"1793_CR19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/OLQ.0000000000001865","volume":"50","author":"PA Chan","year":"2023","unstructured":"Chan PA, Le Brazidec DL, Becasen JS, et al. Safety of longer-term doxycycline use: a systematic review and meta-analysis with implications for bacterial sexually transmitted infection chemoprophylaxis. Sex Transm Dis. 2023;50:701\u201312. https:\/\/doi.org\/10.1097\/OLQ.0000000000001865.","journal-title":"Sex Transm Dis"},{"key":"1793_CR20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/archinte.159.3.266","volume":"159","author":"RK Ailani","year":"1999","unstructured":"Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1999;159:266\u201370. https:\/\/doi.org\/10.1001\/archinte.159.3.266.","journal-title":"Arch Intern Med"},{"key":"1793_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/j.jvca.2006.09.006","volume":"21","author":"RD Stevens","year":"2007","unstructured":"Stevens RD, Wu CL. Strengths and limitations of meta-analysis. J Cardiothorac Vasc Anesth. 2007;21:1\u20132. https:\/\/doi.org\/10.1053\/j.jvca.2006.09.006.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"1793_CR22","unstructured":"Zhong J. Diagnosis and treatment guidelines for Mycoplasma pneumoniae pneumonia in children (2023 edition). Xin Fa Chuan Ran Bing Dian Zi Za Zhi. 2024;9:73\u20139."},{"key":"1793_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101103","volume":"47","author":"KHS Dungu","year":"2024","unstructured":"Dungu KHS, Holm M, Hartling U, et al. Mycoplasma pneumoniae incidence, phenotype, and severity in children and adolescents in Denmark before, during, and after the COVID-19 pandemic: a nationwide multicentre population-based cohort study. Lancet Reg Health. 2024;47: 101103. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101103.","journal-title":"Lancet Reg Health"},{"key":"1793_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12879-020-4810-9","volume":"20","author":"E Lee","year":"2020","unstructured":"Lee E, Kim CH, Lee YJ, et al. Annual and seasonal patterns in etiologies of pediatric community-acquired pneumonia due to respiratory viruses and Mycoplasma pneumoniae requiring hospitalization in South Korea. BMC Infect Dis. 2020;20:132. https:\/\/doi.org\/10.1186\/s12879-020-4810-9.","journal-title":"BMC Infect Dis"},{"key":"1793_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/cod.13803","volume":"84","author":"J Geier","year":"2021","unstructured":"Geier J, Schubert S, Schnuch A, et al. A negative breakdown test in a fragrance mix I-positive patient does not rule out contact allergy to its fragrance constituents. Contact Dermatitis. 2021;84:407\u201318. https:\/\/doi.org\/10.1111\/cod.13803.","journal-title":"Contact Dermatitis"},{"key":"1793_CR26","doi-asserted-by":"publisher","DOI":"10.4110\/in.2021.21.e1","volume":"21","author":"YW Kang","year":"2021","unstructured":"Kang YW, Park S, Lee KJ, Moon D, Kim YM, Lee SW. Understanding the host innate immune responses against SARS-CoV-2 infection and COVID-19 pathogenesis. Immune Netw. 2021;21: e1. https:\/\/doi.org\/10.4110\/in.2021.21.e1.","journal-title":"Immune Netw"},{"key":"1793_CR27","unstructured":"Smith M, Tomboc PJ, Markovich B. Fibrolamellar hepatocellular carcinoma, in StatPearls. 2025: Treasure Island (FL) ineligible companies. Disclosure: Patrick Tomboc declares no relevant financial relationships with ineligible companies. Disclosure: Brian Markovich declares no relevant financial relationships with ineligible companies."},{"key":"1793_CR28","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1016\/j.vaccine.2021.05.023","volume":"39","author":"S Tufail","year":"2021","unstructured":"Tufail S, Shah MA, Zafar M, et al. Identification of potent epitopes on hexon capsid protein and their evaluation as vaccine candidates against infections caused by members of Adenoviridae family. Vaccine. 2021;39:3560\u20134. https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.023.","journal-title":"Vaccine"},{"key":"1793_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jmii.2020.10.002","volume":"54","author":"TA Tsai","year":"2021","unstructured":"Tsai TA, Tsai CK, Kuo KC, Yu HR. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J Microbiol Immunol Infect. 2021;54:557\u201365. https:\/\/doi.org\/10.1016\/j.jmii.2020.10.002.","journal-title":"J Microbiol Immunol Infect"},{"key":"1793_CR30","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s00431-024-05519-1","volume":"183","author":"G Ding","year":"2024","unstructured":"Ding G, Zhang X, Vinturache A, van Rossum AMC, Yin Y, Zhang Y. Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia. Eur J Pediatr. 2024;183:3001\u201311. https:\/\/doi.org\/10.1007\/s00431-024-05519-1.","journal-title":"Eur J Pediatr"},{"key":"1793_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00405-6","volume":"5","author":"H Li","year":"2024","unstructured":"Li H, Li S, Yang H, Chen Z, Zhou Z. Resurgence of Mycoplasma pneumonia by macrolide-resistant epidemic clones in China. Lancet Microbe. 2024;5: e515. https:\/\/doi.org\/10.1016\/S2666-5247(23)00405-6.","journal-title":"Lancet Microbe"},{"key":"1793_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00086-7","volume":"5","author":"Y Chen","year":"2024","unstructured":"Chen Y, Li X, Fu Y, Yu Y, Zhou H. Whole-genome sequencing unveils the outbreak of Mycoplasma pneumoniae in mainland China. Lancet Microbe. 2024;5: 100870. https:\/\/doi.org\/10.1016\/S2666-5247(24)00086-7.","journal-title":"Lancet Microbe"},{"key":"1793_CR33","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.19381\/j.issn.1001-7585.2024.21.033","volume":"37","author":"XQ Qiu","year":"2024","unstructured":"Qiu XQ, He NH, Zhang XZ, Huang SW, Huang YS. Efficacy and safety of doxycycline in the treatment of Mycoplasma pneumoniae pneumonia in children. Yi Xue Li Lun Yu Shi Jian. 2024;37:3693\u20136. https:\/\/doi.org\/10.19381\/j.issn.1001-7585.2024.21.033.","journal-title":"Yi Xue Li Lun Yu Shi Jian."},{"key":"1793_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.16662\/j.cnki.1674-0742.2024.25.119","volume":"43","author":"X Yang","year":"2024","unstructured":"Yang X, Li Y. Clinical application of sequential therapy of doxycycline and azithromycin in children with Mycoplasma pneumoniae pneumonia. Zhong Wai Yi Liao. 2024;43:119\u201322. https:\/\/doi.org\/10.16662\/j.cnki.1674-0742.2024.25.119.","journal-title":"Zhong Wai Yi Liao."},{"key":"1793_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.19368\/j.cnki.2096-1782.2024.09.157","volume":"9","author":"Y Chen","year":"2024","unstructured":"Chen Y. Analysis of the effect of doxycycline in the treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Xi Tong Yi Xue. 2024;9:157\u201360. https:\/\/doi.org\/10.19368\/j.cnki.2096-1782.2024.09.157.","journal-title":"Xi Tong Yi Xue."},{"key":"1793_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.13407\/j.cnki.jpp.1672-108X.2021.10.003","volume":"27","author":"Y Pang","year":"2021","unstructured":"Pang Y, Lei XM, Jiang NJ, Zhu SY, Zhu DJ. Application value of doxycycline in children with severe Mycoplasma pneumoniae pneumonia. Er Ke Yao Xue Za Zhi. 2021;27:9\u201311. https:\/\/doi.org\/10.13407\/j.cnki.jpp.1672-108X.2021.10.003.","journal-title":"Er Ke Yao Xue Za Zhi."},{"key":"1793_CR37","first-page":"3108","volume":"34","author":"XQ Cui","year":"2024","unstructured":"Cui XQ, Han GH, Ren QB. Efficacy of doxycycline in treating azithromycin-resistant Mycoplasma pneumoniae pneumonia in children. Zhonghua Yi Yuan Gan Ran Xue Za Zhi. 2024;34:3108\u201312.","journal-title":"Zhonghua Yi Yuan Gan Ran Xue Za Zhi"},{"key":"1793_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.13407\/j.cnki.jpp.1672-108X.2024.09.006","volume":"30","author":"GM Shen","year":"2024","unstructured":"Shen GM, Hu WJ, Jia SW. Observation of the efficacy of doxycycline combined with methylprednisolone in treating refractory Mycoplasma pneumoniae pneumonia in children. Er Ke Yao Xue Za Zhi. 2024;30:24\u20137. https:\/\/doi.org\/10.13407\/j.cnki.jpp.1672-108X.2024.09.006.","journal-title":"Er Ke Yao Xue Za Zhi."},{"key":"1793_CR39","first-page":"92","volume":"64","author":"YF Chen","year":"2024","unstructured":"Chen YF, Yu XH, Yang F. Comparative study of intravenous azithromycin and doxycycline in the treatment of Mycoplasma pneumoniae pneumonia in children. Shandong Yi Yao. 2024;64:92\u20136.","journal-title":"Shandong Yi Yao"},{"key":"1793_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.15887\/j.cnki.13-1389\/r.2024.31.039","volume":"17","author":"J Fu","year":"2024","unstructured":"Fu J. Clinical efficacy and safety of doxycycline combined with azithromycin in the treatment of Mycoplasma pneumoniae pneumonia in children. Lin Chuang He Li Yong Yao. 2024;17:134\u20136. https:\/\/doi.org\/10.15887\/j.cnki.13-1389\/r.2024.31.039.","journal-title":"Lin Chuang He Li Yong Yao."},{"key":"1793_CR41","first-page":"139","volume":"7","author":"XJ He","year":"2015","unstructured":"He XJ. Observation of the efficacy of doxycycline combined with macrolides in treating refractory Mycoplasma pneumoniae pneumonia. Zhong Guo Zhong Xi Yi Jie He Er Ke Xue. 2015;7:139\u201341.","journal-title":"Zhong Guo Zhong Xi Yi Jie He Er Ke Xue"},{"key":"1793_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.20148\/j.fmj.2024.06.015","volume":"46","author":"FX Xiao","year":"2024","unstructured":"Xiao FX, Zhang XC. Clinical efficacy of doxycycline combined with Fei Li Ke oral liquid in the treatment of Mycoplasma pneumoniae pneumonia in children. Fu Jian Yi Yao Za Zhi. 2024;46:48\u201351. https:\/\/doi.org\/10.20148\/j.fmj.2024.06.015.","journal-title":"Fu Jian Yi Yao Za Zhi."},{"key":"1793_CR43","first-page":"1025","volume":"19","author":"XR Tao","year":"2021","unstructured":"Tao XR, Duan YY, Dong LL, Liu XL, Pei BF, Ma SL. Safety and efficacy analysis of levofloxacin and doxycycline in the treatment of refractory Mycoplasma pneumoniae pneumonia in children. Zhong Nan Yao Xue. 2021;19:1025\u20138.","journal-title":"Zhong Nan Yao Xue"},{"key":"1793_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.15887\/j.cnki.13-1389\/r.2024.20.040","volume":"17","author":"MS Zhou","year":"2024","unstructured":"Zhou MS. Clinical efficacy and safety of doxycycline in the treatment of Mycoplasma pneumoniae pneumonia in children. Lin Chuang He Li Yong Yao. 2024;17:137\u20139. https:\/\/doi.org\/10.15887\/j.cnki.13-1389\/r.2024.20.040.","journal-title":"Lin Chuang He Li Yong Yao."},{"key":"1793_CR45","first-page":"2307","volume":"39","author":"DG Zhang","year":"2024","unstructured":"Zhang DG, Yang QS, Zhao XZ. Clinical study on compound pholcodine combined with doxycycline in treating macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Xian Dai Yao Wu Yu Lin Chuang. 2024;39:2307\u201311.","journal-title":"Xian Dai Yao Wu Yu Lin Chuang"},{"key":"1793_CR46","first-page":"1152","volume":"38","author":"M Zhang","year":"2023","unstructured":"Zhang M, Chu WH, Xu CX, Ma YY, Peng S. Clinical study of Huaiqihuang granules combined with doxycycline in the treatment of Mycoplasma pneumoniae pneumonia in children. Xian Dai Yao Wu Yu Lin Chuang. 2023;38:1152\u20135.","journal-title":"Xian Dai Yao Wu Yu Lin Chuang"},{"key":"1793_CR47","first-page":"2495","volume":"38","author":"CJ Feng","year":"2023","unstructured":"Feng CJ, Zhang XY, Bai JQ, Li TT. Clinical study of Qingxuan Zhike granules combined with doxycycline in the treatment of Mycoplasma pneumoniae pneumonia in children. Xian Dai Yao Wu Yu Lin Chuang. 2023;38:2495\u20139.","journal-title":"Xian Dai Yao Wu Yu Lin Chuang"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01793-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:50:17Z","timestamp":1764917417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01793-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1793"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01793-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Clinical Ethics Committee of The First Affiliated Hospital of Bengbu Medical University (No. [2024] 212).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"259"}}